Osteoarthritis (OA) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Osteoarthritis Emerging Therapy and TPP Insights

Thelansis’s “Osteoarthritis (OA) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Osteoarthritis Overview

Osteoarthritis is a progressive whole-joint disease involving articular cartilage loss, subchondral bone changes, and synovial inflammation, resulting in pain, stiffness, and impaired mobility. Current management remains primarily symptom- and function-focused, using exercise, rehabilitation, weight management where appropriate, analgesics and NSAIDs, and selected intra-articular treatments to improve symptoms rather than reliably halt structural progression. For patients with advanced symptomatic disease who remain significantly impaired despite conservative treatment, joint arthroplasty provides an established definitive option. The major therapeutic gap is the absence of an approved disease-modifying osteoarthritis drug (DMOAD) capable of meaningfully altering both structural progression and clinical outcomes. This is driving development of targeted molecular therapies, regenerative and cellular approaches, and localized intra-articular delivery strategies. A key 2026 milestone is the regulatory advancement of lorecivivint, a dual CLK/DYRK kinase inhibitor being developed as a potential first DMOAD. Other investigational programs, including intra-articular TPX-100 and cell-based approaches, reflect continued efforts to combine symptom improvement with structural preservation. For stakeholders, OA represents a high-value therapeutic frontier where the central challenge is moving beyond symptom control toward demonstrable disease modification.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)